**Table 1. Characteristics of the patients with pancreatic cancer under palliative treatments**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Treatment group** | **p value** |
| **RCT + DRT (n = 33)** | **RCT (n = 38)** |
| Gender, n (%): |  |  |  |
| Male | 18 (54.6) | 22 (57.9) | 0.8 |
| Female | 15 (45.4) | 16 (42.1) |  |
| Mean age, years (min-max) | 70.0 (50–83) | 66.5 (58–83) | 0.3 |
| ECOG status, N (%): |  |  |  |
| 1 | 22 (66.7) | 23 (60.5) | 0.6 |
| 2 | 11 (33.3) | 15 (39.5) |  |
| History of mechanical jaundice, N (%) | 24 (72.7) | 31 (81.6) | 0.4 |
| Mean tumor size, mm | 37.3 ± 1.6 | 41.5 ± 1.4 | 0.1 |
| Tumor size, N (%): |  |  |  |
| T2 | 12 (36.4) | 10 (26.3) | 0.4 |
| T3 | 21 (63.6) | 28 (73.7) |  |
| Regional metastases, N (%): |  |  |  |
| N0 | 15 (45.5) | 17 (44.7) | 1 |
| N1 | 18 (54.5) | 21 (55.3) |  |
| Stage of the pancreatic cancer, N (%) |  |  |  |
| IB | 5 (15.1) | 3 (7.9) | 0.6 |
| IIA | 12 (36.4) | 16 (42.1) |  |
| IIB | 16 (48.5) | 19 (50.0) |  |
| Tumor differentiation grade, N (%): |  |  |  |
| G1 | 5 (15.2) | 5 (13.1) | 0.9 |
| G2 | 17 (51.5) | 18 (47.4) |  |
| G3 | 11 (33.3) | 15 (39.5) |  |
| СА 19-9 levels, N (%): |  |  |  |
| < 1000 U/mL | 14 (42.4) | 14 (36.8) | 0.6 |
| > 1000 U/mL | 19 (57.6) | 24 (63.2) |  |

ECOG, Eastern Cooperative Oncology Group; RCT, regional chemotherapy alone; RCT + DRT, regional chemotherapy followed by daily split-dose distant radiation therapy

**Table 2. Toxicities (NCI CTCAE, v. 5.0 criteria) off the palliative treatment in the patients with pancreatic cancer**

|  |  |  |
| --- | --- | --- |
| **Toxicity rate (N)\*** | **Treatment group\*\*** | **p value** |
| **RCT + DRT (n = 33)** | **RCT (n = 38)** |
| Hematological toxicity grade 1–2 (n = 53): | 28 (84.8) | 25 (65.8) | 0.07 |
| Anemia (n = 21) | 10 (30.3) | 11 (29.0) | 0.9 |
| Leukopenia / neutropenia (n = 31) | 16 (48.5) | 15 (39.5) | 0.45 |
| Thrombocytopenia (n = 41) | 21 (63.6) | 20 (52.6) | 0.35 |
| Gastrointestinal toxicity grade 1-2 (n = 21) | 11 (33.3) | 10 (26.3) | 0.52 |
| Total number of patients, N (%) | 31 (93.9) | 32 (84.2) | 0.27 |

RCT, regional chemotherapy alone; RCT + DRT, regional chemotherapy followed by daily split-dose distant radiation therapy

\* Several toxicities could occur in one and the same patients

\*\* The values are given as absolute numbers of toxicity events and the proportion of the patients with toxicities from the total number of the patients in the study group

**Table 3. Long-term results of the palliative treatment of the pancreatic cancer patients**

|  |  |  |
| --- | --- | --- |
| **Endpoints** | **Treatment group** | **P value** |
| **RCT + DRT (n = 33)** | **RCT (n = 38)** |
| Response to treatment, N (%) |  |  |  |
| Partial | 2 (6.0) | 0 (0) | 0.03 |
| Stabilization | 16 (48.5) | 10 (26.3) |  |
| Progression | 15 (45.5) | 28 (73.7) |  |
| Median time to progression, months [95% CI] | 7.8 [6.9–8.4] | 6.0 [5.2–6.3] | < 0.05 |
| Progression, N (%): |  |  |  |
| Locoregional | 4 (12.1) | 13 (34.2) | 0.03 |
| Distant metastases | 24 (72.7) | 16 (42.1) |  |
| No / no information | 5 (15.2) | 9 (23.7) |  |
| One-year survival, % | 50 | 29 | < 0.05 |
| Median overall survival, months [95% CI] | 12.4 [10.5–17.8] | 10.2 [8.9–12.2] | 0.006 |

CI, confidence interval; RCT, regional chemotherapy alone; RCT + DRT, regional chemotherapy followed by daily split-dose distant radiation therapy